Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Simple zinc pill may shield kids with sickle cell from deadly infections

NCT ID NCT06561061

Prevention Sponsor: Indiana University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether daily zinc supplements can lower the number of serious infections in young children with sickle cell anemia. Researchers in Uganda gave 100 children either zinc or a placebo for a period and tracked infections. The goal is to find an affordable, easy-to-use way to protect these children from life-threatening illnesses.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
zinc sulfate
What this could lead to
If zinc proves effective, it could offer a simple, low-cost way to reduce dangerous infections in children with sickle cell disease.
What could go wrong
This is a completed Phase 2/3 trial with only 100 children in Uganda, so results may not apply to other populations. Zinc may not reduce infections enough to change practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2/3

Runs two stages together: whether the treatment works, then large-scale confirmation.

Participants

100 people

The number who actually took part.

Started

Feb 2025

Finished

Nov 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

12 to 59 months

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Documented sickle cell anemia (HbSS supported by hemoglobin electrophoresis) * Age range of 1.00-4.99 years, inclusive, at the time of enrollment * Weight at least 5.0 kg at the time of enrollment * Willingness to comply with all study-related treatments, evaluations, and follow-up * Children whose parents or guardians give full written informed consent Exclusion Criteria: * Known other chronic medical condition (e.g., HIV, malignancy, active clinical tuberculosis) * Severe malnutrition determined by impaired growth parameters as defined by WHO (weight for length/height or height for age z-score \<-3, using WHO growth standards) * Absolute neutropenia (absolute neutrophil count \<500)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Sickle cell disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

sickle cell disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Sickle cell disease

Contacts and locations

Locations

  • Jinja Hospital

    Jinja, Uganda

More trials for these conditions

Other studies related to the condition(s) this trial covers.